{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:10:36Z","timestamp":1792188636604,"version":"4.4.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide have evolved over the past decade from glucose-lowering antidiabetic agents into a cardiovascular drug class with proven outcome benefit across multiple clinical scenarios. This state-of-the-art review synthesizes the cardiovascular evidence base for incretin analogues, organized by clinical scenario, and addresses the structural challenges that constrain their deployment in low- and middle-income countries (LMICs). We review the pharmacology and proposed cardiovascular mechanisms, including direct effects on the vascular endothelium, macrophage inflammation, and epicardial adipose tissue, alongside indirect benefits mediated by weight loss, glycemic control, and blood pressure reduction. We summarize the evidence in five clinical scenarios: type 2 diabetes with established atherosclerotic cardiovascular disease or high cardiovascular risk; overweight or obesity with established cardiovascular disease but without diabetes; obesity-related heart failure with preserved ejection fraction; chronic kidney disease; and symptomatic peripheral artery disease. Pipeline agents (retatrutide, CagriSema, survodutide, orforglipron, zenagamtide, and MariTide) are reviewed alongside their ongoing cardiovascular outcome trials. A dedicated section examines the global access perspective, including the disproportionately high burden of cardiometabolic disease in LMICs, the limited representation of regional populations in pivotal trials, and the structural barriers of cost and reimbursement that constrain access. We close with a practical algorithm for the clinician, an honest assessment of evidence gaps, and a calibrated outlook on the next generation of incretin-based cardiovascular therapy.<\/jats:p>","DOI":"10.3389\/fendo.2026.1898812","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:36:24Z","timestamp":1784871384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Incretin analogues as cardiovascular agents: a state-of-the-art review"],"prefix":"10.3389","volume":"17","author":[{"given":"Diego","family":"Araiza-Garaygordobil","sequence":"first","affiliation":[{"name":"Departamento de Urgencias y Unidad Coronaria, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez","place":["Tlalpan, Ciudad de M\u00e9xico, Mexico"]},{"name":"Divisi\u00f3n de Estudios de Posgrado, Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Coyoac\u00e1n, Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Rico-Fontalvo","sequence":"additional","affiliation":[{"name":"Comit\u00e9 de Ri\u00f1\u00f3n, diabetes y metabolismo, Asociaci\u00f3n Colombiana de Nefrolog\u00eda e HTA","place":["Bogot\u00e1, Colombia"]},{"name":"Department of Nephrology, Nephromedicall Health Services Provider Institution (IPS)","place":["Medell\u00edn, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsabe","family":"Hern\u00e1ndez-Balbuena","sequence":"additional","affiliation":[{"name":"Departamento de Urgencias y Unidad Coronaria, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez","place":["Tlalpan, Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vinay-Coro","sequence":"additional","affiliation":[{"name":"Departamento de Urgencias y Unidad Coronaria, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez","place":["Tlalpan, Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Gonz\u00e1lez-Arias","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Zhou","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.20996\/1819-6446-2007-3-4-71-99","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32261-x","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/nejmoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease SURPASS-CVOTdesign and baseline characteristics","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","article-title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND","volume":"20","author":"Konig","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2021.06.001","article-title":"Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists","volume":"28","author":"Tommerdahl","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes (STEP-HFpEF DM)","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obes (Silver Spring)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-39226-6.00021-7","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure (STEP-HFpEF echocardiography substudy)","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.07.011","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-s010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4471-6657-3_11","article-title":"Heart failure with preserved ejection fraction","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/circulationaha.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199568741.003.0163","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000974","article-title":"Kidney and survival outcomes with semaglutide by CKD severity in the FLOW trial","volume":"21","author":"Tuttle","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s489805","article-title":"Real-world clinical effectiveness of glucagon-like peptide-1 receptor agonist on mild-to-moderate diabetic kidney disease in patients with type 2 diabetes: a retrospective, single-arm clinical trial","volume":"17","author":"Aguilar Casta\u00f1eda","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/1468-0009.12279","article-title":"Comparing generic drug markets in Europe and the United States: prices, volumes, and spending","volume":"95","author":"Wouters","year":"2017","journal-title":"Milbank Q"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1898812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:36:25Z","timestamp":1784871385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1898812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":54,"alternative-id":["10.3389\/fendo.2026.1898812"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1898812","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1898812"}}